InvestorsHub Logo
icon url

AugustaFriends

06/16/21 8:24 AM

#505779 RE: Crazy Money #505777

$APRE Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint https://finance.yahoo.com/news/aprea-therapeutics-announces-phase-1-120000137.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo